Literature DB >> 31456060

Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis.

Daisuke Ito1, Atsushi Hashizume2, Yasuhiro Hijikata1, Shinichiro Yamada1, Yohei Iguchi1, Madoka Iida1, Yoshiyuki Kishimoto1, Hideyuki Moriyoshi1, Akihiro Hirakawa3, Masahisa Katsuno4.   

Abstract

OBJECTIVE: To assess the changes of muscle-related biomarkers at the early stage of amyotrophic lateral sclerosis, and to confirm these findings in an experimental animal model.
METHODS: Thirty-nine subjects with sporadic amyotrophic lateral sclerosis and 20 healthy controls were enrolled and longitudinally evaluated. We evaluated serum creatine kinase and creatinine levels and appendicular lean soft-tissue mass using dual X-ray absorptiometry. The levels of biomarkers at early ALS stages were estimated using linear mixed models with unstructured correlation and random intercepts. We also analyzed the longitudinal changes of serum creatine kinase and creatinine, together with the mRNA levels of acetylcholine receptor subunit γ (Chrng) and muscle-associated receptor tyrosine kinase, markers of denervation, in the gastrocnemius muscle of superoxide dismutase 1 (SOD1)G93A transgenic mice, an animal model of amyotrophic lateral sclerosis.
RESULTS: The estimated levels of creatine kinase were higher in subjects with amyotrophic lateral sclerosis at the early stage than in healthy controls, although the estimated appendicular lean soft-tissue mass and creatinine levels were equivalent between both groups, suggesting that the elevation of creatine kinase precedes both muscular atrophy and subjective motor symptoms in sporadic amyotrophic lateral sclerosis. In SOD1G93A mice, the serum levels of creatine kinase were elevated at 9 weeks of age (peri-onset) when Chrng started to be up-regulated, and were then down-regulated at 15 weeks of age, consistent with the clinical data from patients with sporadic amyotrophic lateral sclerosis.
INTERPRETATION: Creatine kinase elevation precedes muscular atrophy and reflects muscle denervation at the early stage.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Biomarker; Creatine kinase

Mesh:

Substances:

Year:  2019        PMID: 31456060     DOI: 10.1007/s00415-019-09507-6

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  48 in total

Review 1.  Amyotrophic lateral sclerosis.

Authors:  L P Rowland; N A Shneider
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

2.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Authors:  Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan
Journal:  Lancet Neurol       Date:  2013-09-04       Impact factor: 44.182

3.  Advances in the prevention of Alzheimer's disease and dementia.

Authors:  A Solomon; F Mangialasche; E Richard; S Andrieu; D A Bennett; M Breteler; L Fratiglioni; B Hooshmand; A S Khachaturian; L S Schneider; I Skoog; M Kivipelto
Journal:  J Intern Med       Date:  2014-03       Impact factor: 8.989

4.  Creatine kinase level and its relationship with quantitative electromyographic characteristics in amyotrophic lateral sclerosis.

Authors:  Hongfei Tai; Liying Cui; Mingsheng Liu; Yuzhou Guan; Xiaoguang Li; Dongchao Shen; Kang Zhang; Shuangwu Liu; Shuang Wu; Qingyun Ding; Youfang Hu
Journal:  Clin Neurophysiol       Date:  2018-02-20       Impact factor: 3.708

5.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.

Authors:  G Bensimon; L Lacomblez; V Meininger
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

6.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

7.  Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis.

Authors:  M K Rafiq; E Lee; M Bradburn; C J McDermott; P J Shaw
Journal:  Eur J Neurol       Date:  2016-03-31       Impact factor: 6.089

8.  Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers.

Authors:  Axel Freischmidt; Kathrin Müller; Lisa Zondler; Patrick Weydt; Alexander E Volk; Anže Lošdorfer Božič; Michael Walter; Michael Bonin; Benjamin Mayer; Christine A F von Arnim; Markus Otto; Christoph Dieterich; Karlheinz Holzmann; Peter M Andersen; Albert C Ludolph; Karin M Danzer; Jochen H Weishaupt
Journal:  Brain       Date:  2014-09-05       Impact factor: 13.501

Review 9.  Amyotrophic lateral sclerosis.

Authors:  Lokesh C Wijesekera; P Nigel Leigh
Journal:  Orphanet J Rare Dis       Date:  2009-02-03       Impact factor: 4.123

10.  Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort.

Authors:  Valentina Gallo; Petra A Wark; Mazda Jenab; Neil Pearce; Carol Brayne; Roel Vermeulen; Peter M Andersen; Goran Hallmans; Andreas Kyrozis; Nicola Vanacore; Mariam Vahdaninia; Verena Grote; Rudolf Kaaks; Amalia Mattiello; H Bas Bueno-de-Mesquita; Petra H Peeters; Ruth C Travis; Jesper Petersson; Oskar Hansson; Larraitz Arriola; Juan-Manuel Jimenez-Martin; Anne Tjønneland; Jytte Halkjær; Claudia Agnoli; Carlotta Sacerdote; Catalina Bonet; Antonia Trichopoulou; Diana Gavrila; Kim Overvad; Elisabete Weiderpass; Domenico Palli; J Ramón Quirós; Rosario Tumino; Kay-Tee Khaw; Nicholas Wareham; Aurelio Barricante-Gurrea; Veronika Fedirko; Pietro Ferrari; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Heiner Boeing; Matthaeus Vigl; Lefkos Middleton; Elio Riboli; Paolo Vineis
Journal:  Neurology       Date:  2013-02-06       Impact factor: 9.910

View more
  8 in total

1.  A phase II open label clinical study of the safety, tolerability and efficacy of ILB® for Amyotrophic Lateral Sclerosis.

Authors:  Ann Logan; Zsuzsanna Nagy; Nicholas M Barnes; Antonio Belli; Valentina Di Pietro; Barbara Tavazzi; Giuseppe Lazzarino; Giacomo Lazzarino; Lars Bruce; Lennart I Persson
Journal:  PLoS One       Date:  2022-05-25       Impact factor: 3.752

2.  Aberrations of biochemical indicators in amyotrophic lateral sclerosis: a systematic review and meta-analysis.

Authors:  Yangfan Cheng; Yongping Chen; Huifang Shang
Journal:  Transl Neurodegener       Date:  2021-01-08       Impact factor: 8.014

3.  Swim training affects Akt signaling and ameliorates loss of skeletal muscle mass in a mouse model of amyotrophic lateral sclerosis.

Authors:  Karol Cieminski; Damian Jozef Flis; Katarzyna Dzik; Jan Jacek Kaczor; Emilia Czyrko; Malgorzata Halon-Golabek; Mariusz Roman Wieckowski; Jedrzej Antosiewicz; Wieslaw Ziolkowski
Journal:  Sci Rep       Date:  2021-10-22       Impact factor: 4.379

4.  Analysis of routine blood parameters in patients with amyotrophic lateral sclerosis and evaluation of a possible correlation with disease progression-a multicenter study.

Authors:  Nora Hertel; Magdalena Kuzma-Kozakiewicz; Marta Gromicho; Julian Grosskreutz; Mamede de Carvalho; Hilmi Uysal; Reinhard Dengler; Susanne Petri; Sonja Körner
Journal:  Front Neurol       Date:  2022-07-27       Impact factor: 4.086

5.  Creatine kinase and prognosis in amyotrophic lateral sclerosis: a literature review and multi-centre cohort analysis.

Authors:  Jiali Gao; Thanuja Dharmadasa; Andrea Malaspina; Pamela J Shaw; Kevin Talbot; Martin R Turner; Alexander G Thompson
Journal:  J Neurol       Date:  2022-05-25       Impact factor: 6.682

6.  Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment.

Authors:  Maren Freigang; Claudia D Wurster; Tim Hagenacker; Benjamin Stolte; Markus Weiler; Christoph Kamm; Olivia Schreiber-Katz; Alma Osmanovic; Susanne Petri; Alexander Kowski; Thomas Meyer; Jan C Koch; Isabell Cordts; Marcus Deschauer; Paul Lingor; Elisa Aust; Daniel Petzold; Albert C Ludolph; Björn Falkenburger; Andreas Hermann; René Günther
Journal:  Ann Clin Transl Neurol       Date:  2021-03-31       Impact factor: 4.511

7.  Combined Treatment with Bojungikgi-Tang and Riluzole Regulates Muscle Metabolism and Dysfunction in the hSOD1G93A Mouse Model.

Authors:  Mudan Cai; Eun Jin Yang
Journal:  Antioxidants (Basel)       Date:  2022-03-18

8.  Untargeted metabolomics yields insight into ALS disease mechanisms.

Authors:  Stephen A Goutman; Jonathan Boss; Kai Guo; Fadhl M Alakwaa; Adam Patterson; Sehee Kim; Masha Georges Savelieff; Junguk Hur; Eva L Feldman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-09-14       Impact factor: 13.654

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.